Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels

Chien Chun Steven Pai, Hui Hua Hsiao, Kai Sun, Mingyi Chen, Takeshi Hagino, Joseph Tellez, Christine Mall, Bruce R. Blazar, Arta M Monjazeb, Mehrdad Abedi, William J Murphy

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Bortezomib, a proteasome inhibitor capable of direct antitumor effects, has been shown to prevent acute graft-versus-host disease (GVHD) when administered in a short course immediately after bone marrow transplantation (BMT) in mice. However, when bortezomib is given continuously, CD4+ Tcell-mediated gastrointestinal tract damage increases GVHD mortality. To investigate the protective effects of bortezomib on other organs, we used a CD8-dependent acute GVHD (aGVHD) model of C3H.SW donor Tcells engrafted into irradiated C57BL/6 recipients (minor MHC mismatch), which lack significant gut GVHD. Our data in this model show that bortezomib can be given continuously to prevent and treat aGVHD mediated by CD8+ Tcells, but this effect is organ specific, such that only skin, and not liver, protection was observed. Despite the lack of hepatic protection, bortezomib still significantly improved survival, primarily because of its skin protection. Reduced skin GVHD by bortezomib was correlated with reduced serum and skin IL-6 levels. Administration of a blocking IL-6 antibody in this model also resulted in similar cutaneous GVHD protection. These results indicate that bortezomib or blockade of IL-6 may prevent CD8+ Tcell-mediated cutaneous acute GVHD.

Original languageEnglish (US)
Pages (from-to)1899-1904
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Graft vs Host Disease
Interleukin-6
Skin
Therapeutics
Proteasome Inhibitors
Liver
Bortezomib
Bone Marrow Transplantation
Gastrointestinal Tract
Mortality
Antibodies
Serum

Keywords

  • Anti-IL-6 therapy
  • Bortezomib
  • Skin acute graft-versus-host disease

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels. / Pai, Chien Chun Steven; Hsiao, Hui Hua; Sun, Kai; Chen, Mingyi; Hagino, Takeshi; Tellez, Joseph; Mall, Christine; Blazar, Bruce R.; Monjazeb, Arta M; Abedi, Mehrdad; Murphy, William J.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 12, 01.12.2014, p. 1899-1904.

Research output: Contribution to journalArticle

Pai, Chien Chun Steven ; Hsiao, Hui Hua ; Sun, Kai ; Chen, Mingyi ; Hagino, Takeshi ; Tellez, Joseph ; Mall, Christine ; Blazar, Bruce R. ; Monjazeb, Arta M ; Abedi, Mehrdad ; Murphy, William J. / Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 12. pp. 1899-1904.
@article{9994a53ed3d3435585588780ef93e2f4,
title = "Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels",
abstract = "Bortezomib, a proteasome inhibitor capable of direct antitumor effects, has been shown to prevent acute graft-versus-host disease (GVHD) when administered in a short course immediately after bone marrow transplantation (BMT) in mice. However, when bortezomib is given continuously, CD4+ Tcell-mediated gastrointestinal tract damage increases GVHD mortality. To investigate the protective effects of bortezomib on other organs, we used a CD8-dependent acute GVHD (aGVHD) model of C3H.SW donor Tcells engrafted into irradiated C57BL/6 recipients (minor MHC mismatch), which lack significant gut GVHD. Our data in this model show that bortezomib can be given continuously to prevent and treat aGVHD mediated by CD8+ Tcells, but this effect is organ specific, such that only skin, and not liver, protection was observed. Despite the lack of hepatic protection, bortezomib still significantly improved survival, primarily because of its skin protection. Reduced skin GVHD by bortezomib was correlated with reduced serum and skin IL-6 levels. Administration of a blocking IL-6 antibody in this model also resulted in similar cutaneous GVHD protection. These results indicate that bortezomib or blockade of IL-6 may prevent CD8+ Tcell-mediated cutaneous acute GVHD.",
keywords = "Anti-IL-6 therapy, Bortezomib, Skin acute graft-versus-host disease",
author = "Pai, {Chien Chun Steven} and Hsiao, {Hui Hua} and Kai Sun and Mingyi Chen and Takeshi Hagino and Joseph Tellez and Christine Mall and Blazar, {Bruce R.} and Monjazeb, {Arta M} and Mehrdad Abedi and Murphy, {William J}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.bbmt.2014.07.022",
language = "English (US)",
volume = "20",
pages = "1899--1904",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels

AU - Pai, Chien Chun Steven

AU - Hsiao, Hui Hua

AU - Sun, Kai

AU - Chen, Mingyi

AU - Hagino, Takeshi

AU - Tellez, Joseph

AU - Mall, Christine

AU - Blazar, Bruce R.

AU - Monjazeb, Arta M

AU - Abedi, Mehrdad

AU - Murphy, William J

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Bortezomib, a proteasome inhibitor capable of direct antitumor effects, has been shown to prevent acute graft-versus-host disease (GVHD) when administered in a short course immediately after bone marrow transplantation (BMT) in mice. However, when bortezomib is given continuously, CD4+ Tcell-mediated gastrointestinal tract damage increases GVHD mortality. To investigate the protective effects of bortezomib on other organs, we used a CD8-dependent acute GVHD (aGVHD) model of C3H.SW donor Tcells engrafted into irradiated C57BL/6 recipients (minor MHC mismatch), which lack significant gut GVHD. Our data in this model show that bortezomib can be given continuously to prevent and treat aGVHD mediated by CD8+ Tcells, but this effect is organ specific, such that only skin, and not liver, protection was observed. Despite the lack of hepatic protection, bortezomib still significantly improved survival, primarily because of its skin protection. Reduced skin GVHD by bortezomib was correlated with reduced serum and skin IL-6 levels. Administration of a blocking IL-6 antibody in this model also resulted in similar cutaneous GVHD protection. These results indicate that bortezomib or blockade of IL-6 may prevent CD8+ Tcell-mediated cutaneous acute GVHD.

AB - Bortezomib, a proteasome inhibitor capable of direct antitumor effects, has been shown to prevent acute graft-versus-host disease (GVHD) when administered in a short course immediately after bone marrow transplantation (BMT) in mice. However, when bortezomib is given continuously, CD4+ Tcell-mediated gastrointestinal tract damage increases GVHD mortality. To investigate the protective effects of bortezomib on other organs, we used a CD8-dependent acute GVHD (aGVHD) model of C3H.SW donor Tcells engrafted into irradiated C57BL/6 recipients (minor MHC mismatch), which lack significant gut GVHD. Our data in this model show that bortezomib can be given continuously to prevent and treat aGVHD mediated by CD8+ Tcells, but this effect is organ specific, such that only skin, and not liver, protection was observed. Despite the lack of hepatic protection, bortezomib still significantly improved survival, primarily because of its skin protection. Reduced skin GVHD by bortezomib was correlated with reduced serum and skin IL-6 levels. Administration of a blocking IL-6 antibody in this model also resulted in similar cutaneous GVHD protection. These results indicate that bortezomib or blockade of IL-6 may prevent CD8+ Tcell-mediated cutaneous acute GVHD.

KW - Anti-IL-6 therapy

KW - Bortezomib

KW - Skin acute graft-versus-host disease

UR - http://www.scopus.com/inward/record.url?scp=84912104023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912104023&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.07.022

DO - 10.1016/j.bbmt.2014.07.022

M3 - Article

C2 - 25064746

AN - SCOPUS:84912104023

VL - 20

SP - 1899

EP - 1904

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -